Rex Bionics Plc
("Rex Bionics" or the "Company")
Results of Annual General Meeting
27 September 2016: Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users and enables robot assisted physiotherapy exercise, today announces that at its Annual General Meeting held today all resolutions proposed were duly passed as follows:
1. To receive the Report of the Directors and Financial Statements for the period ending 31 March 2015 together with the report from the auditors.
2. To approve the Remuneration Report of the Board as set out in the Financial Statements.
3. To reappoint Messrs Grant Thornton, Chartered Accountants and Statutory Auditors, as auditors of the Company and authorize the Directors to fix their remuneration.
4. To re-elect as a Director David Macfarlane who retires in accordance with Article 35.2 and offers himself for re-election
5. To re-elect as a Director John Plimmer who retires in accordance with Article 35.2 and offers himself for re-election.
6 To re-elect as a Director Victoria Provis who retires in accordance with Article 35.2 and offers himself for re-election
7 To reappoint as a Director Joe Cucolo who retires in accordance with Article 30.2 and offers himself for reappointment
8. To grant to the Board generally and unconditionally authority in accordance with section 551 of the Companies Act 2006 as amended (the "Act") such authority to replace all existing authorities granted to the Board pursuant to section 551 of the Act to allow relevant securities (within the meaning of section 551 of the Act) provided that this power is limited to a maximum aggregate amount of £1,500,000, such authority to expire on 30th September 2017 or if earlier, the conclusion of the Company's annual general meeting to be held in 2017 save that the Company may prior to such expiry make an offer or agreement which would or might require relevant securities to be allotted or granted after the expiry of such period and the Board may allot relevant securities in in pursuant of any such offer or agreement as if the authority had not expired.
9. To empower the Board in accordance with section 570 of the Act to allot equity securities (as defined in section 560(1) of the Act) for cash, pursuant to the authority conferred on it by Resolution 8, as if section 561(1) of the Act did not apply to any such allotment, such authority to replace all existing authorities to disapply section 561(1) of the Act provided that this power shall be limited to the allotment of equity securities:
a. up to an aggregate nominal amount of £250,000 for the purposes of being able to grant options to employees
b. Up to an additional amount of £1,250,000
c. shall expire on 30th September 2017 or, if earlier, the conclusion of the annual general meeting to be held in 2017,
save that the Company may prior to such expiry make an offer or agreement which would or might require equity securities to be allotted after expiry of the said period and the Board may allot equity securities in pursuance of such an offer or agreement as if the power had not expired.
For further information please contact:
Rex Bionics Plc
Crispin Simon, Chief Executive Officer
+44 (0) 781 086 6386
Peter Worrall, Chief Financial Officer
+44 (0)1428 645416
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior/Stewart Wallace / Ben Maddision
+44 (0) 20 7710 7600
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Lindsey Neville
+44 (0) 203 709 5700
About Rex Bionics Plc
Rex Bionics (AIM: RXB) is the AIM-listed pioneer of the REX Robot that enhances the mobility of wheelchair users. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics is working with physiotherapists to develop the practice of Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises, designed by specialist physiotherapists.
Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep, cardiovascular performance, maintenance of joint range, and a reduction in common abdominal problems and prescription drug use. A programme of clinical trials is now under way to evaluate these potential benefits.
REX is used by people with complete spinal cord injury, as well as people who have suffered a stroke or other traumatic brain injury; and people with multiple sclerosis and muscular dystrophy. REX P, for use in the home, enables users to walk and stand with their hands free - providing more work and recreation options.
Rex Bionics has been listed on AIM since April 2014. REX is not approved for At-Home use in the United States of America.
For more information please visit, www.rexbionics.com
This information is provided by RNS